This site is intended for healthcare professionals

FDA's Tobacco Product Scientific Advisory Committee likely to make a decision on reduced nicotine content cigarettes by Q2 2020. 22nd Century Group.

Read time: 1 mins
Published:20th Feb 2020
22nd Century Group, Inc. met on 14 February 2020 with the FDA's Tobacco Product Scientific Advisory Committee (TPSAC) to present the Company’s Modified Risk Tobacco Product (MRTP) application for its proprietary, reduced nicotine content cigarettes. This meeting was the first time that TPSAC considered an MRTP application for a modified exposure claim and also TPSAC's first discussion of an application for a combustible tobacco product. The company noted that “Based on the success of the meeting, the FDA’s public statements at the meeting and in its briefing document published ahead of the meeting, as well as the FDA’s previous guidance about the timing of its reviews of MRTP applications in general, it believes the FDA is likely to reach a decision on its MRTP application sometime in the second quarter of this year."
Condition: Nicotine Addiction
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.